1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Straddles The Fence On Antibiotics; Is It About To Fall Off?

 
• By Mary Jo Laffler

The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.

AstraZeneca PLC’s commitment to antibiotic research appears in growing doubt. The company’s CEO Pascal Soriot has made clear that antibiotics are not a core research area, but the company does boast one of the largest antibiotics research initiatives among big pharma today.

However, in a blog post Oct. 21, anti-infectives expert and consultant David Shlaes reported that AstraZeneca has advised its antibiotics...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

BIO Notebook: MFN Pricing, Obesity R&D, US FDA’s Rare Disease Hub And Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day Three of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for the FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.